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Abstract 
The International Conference on Spreading Depolarizations (iCSD) held in Boca Raton, Florida, in the September of 
2018 devoted a section to address the question, “What should a clinician do when spreading depolarizations are 
observed in a patient?” Discussants represented a wide range of expertise, including neurologists, neurointensivists, 
neuroradiologists, neurosurgeons, and pre-clinical neuroscientists, to provide both clinical and basic pathophysiology 
perspectives. A draft summary of viewpoints offered was then written by a multidisciplinary writing group of iCSD 
members, based on a transcript of the session. Feedback of all discussants was formally collated, reviewed, and incor-
porated into the final document which was subsequently approved by all authors.
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Introduction
The Co-Operative Studies on Brain Injury Depolariza-
tions was established in 2003 as a clinical translational 
effort to determine whether spreading depolarizations 
(SD), as observed in animal models of neurological 
injury, could be recorded and related to outcomes after 
human brain injury. Using electrocorticographic (ECoG) 
monitoring from subdural electrode strips, those initial 
studies yielded the surprising result that SD incidences 
range from 55 to 90% in patients who have undergone 
neurosurgical treatment of brain trauma, ruptured 
aneurysms, intracerebral hemorrhage, or malignant 
hemispheric stroke. Those studies further revealed an 
association of SDs with markers of secondary brain 
injury, such as delayed cerebral ischemia, infarction 
expansion, brain edema, and excitotoxicity, as well as 
poor functional outcome. Based on this work, the pre-
dominant consensus is that SDs have an adverse impact, 
in at least some subset of patients. The accompanying 
discussion article highlights various considerations that 
may determine whether individual SDs are harmful or 
benign.
Given this background, clinicians who monitor patients 
for SDs are now confronted with the question as to what 
should be done, from both ethical and scientific perspec-
tives, when faced with a critically ill patient who has neu-
rologic deficits and ongoing SDs detected with ECoG 
monitoring. The question becomes even more pressing 
with (1) the emerging use of SD monitoring for clinical 
care, rather than research only, and (2) the increasing use 
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in pre-hospital and neurointensive care of the analgesic 
and sedative, ketamine, a clinically available N-methyl-
d-aspartate (NMDA) receptor antagonist. Several physi-
ologic factors have been shown to influence SD, and 
ketamine is perhaps the leading treatment option to sup-
press them, based on published results from multiple 
centers. Yet, no studies to date have investigated whether 
interventions targeted to SD suppression have clini-
cal benefit. Motivated by these considerations, a second 
discussion session was held at the International Confer-
ence on Spreading Depolarizations (iCSD; Boca Raton, 
Florida, September 22–24, 2018), as introduced in the 
accompanying article, to address the question, “What 
should a clinician do when spreading depolarizations 
are observed?” Discussants represented a wide range 
of expertise, including neurologists, neurointensivists, 
neuroradiologists, neurosurgeons, and pre-clinical neu-
roscientists, to provide both clinical and basic patho-
physiology perspectives. This report is a summary of the 
viewpoints offered, based on a transcript of the session.
SDs in the Clinical Context
Discussants from several centers attested to the clinical 
dilemma of whether and how to treat patients showing a 
severe course of SDs. Current approaches and responses 
to this problem vary across centers and even within cent-
ers depending on several factors. Some investigators 
reported that ketamine is frequently used as a response 
when clusters of repetitive SDs are detected on ECoG 
monitoring. Several other sites reported that the trigger 
to initiate treatment depends on the patient’s neurologi-
cal exam or other multimodality monitoring parameters, 
such as changes in brain tissue oxygen tension, brain 
metabolism, or cerebral blood flow. Particularly chal-
lenging are cases where a patient may show improving 
performance on one aspect of a neurological exam (e.g., 
ability to follow commands), but demonstrate persistent 
or increasing numbers of SD events. Specific examples 
of this scenario were raised by a neurointensivist and a 
neurosurgeon at two different medical centers. Cur-
rently, invasive monitoring is often withdrawn in these 
patients despite ongoing SDs, and SD incidence or sever-
ity is not further considered. This common experience 
led to reflection on the purpose of invasive monitoring 
in neurointensive care and whether it is genuinely being 
used to inform treatment of disrupted brain physiology. 
It was pointed out that even when a patient is improv-
ing in terms of consciousness and motor responsiveness, 
SDs may still signal significant injury and cell death that 
are ongoing in brain regions that are not eloquent. The 
patient may recover, even to a good outcome score, yet 
have more subtle cognitive deficits that were perhaps 
preventable if neurointensive management were targeted 
to brain pathology.
Treatment Options
It was noted that the use of ketamine as a primary candi-
date for treatment is a contentious topic in part because 
NMDA receptor antagonists have failed as neuroprotec-
tive agents in multiple clinical trials. However, it is pos-
sible that the failures were due to broad patient inclusion 
criteria, whereas SD monitoring on the other hand would 
allow mechanistic targeting and more selective patient 
inclusion. A further concern was that the ketamine dos-
ing required for SD suppression is fairly high and that 
there may be neurotoxic and sedation-related adverse 
effects on other brain regions, which may go undetected 
and counteract any benefit of SD suppression. This idea 
was challenged, however, by one of the participants with 
experience in refractory status epilepticus, where keta-
mine doses well above 1.5 mg/kg/h (even up to 7.5 mg/
kg/h) are used routinely and successfully. Though poten-
tial harm of these high doses is not fully known, this is 
a well-accepted practice in the field. Others contested 
that significant SD suppression can be obtained at much 
lower doses. Another concern is related to the discussion 
of whether SDs are universally harmful, and whether they 
might have beneficial effects in remote, uninjured regions 
(see accompanying discussion paper). The theoretical 
possibility was raised that ketamine could suppress SD 
in these more remote sites where they may be beneficial, 
but fail to suppress them in vulnerable areas of evolving 
injury. Indeed, several pre-clinical studies have shown 
that NMDA antagonists have reduced efficacy to block 
SDs in ischemic compared to normal tissue. Finally, there 
was concern that ketamine may blunt the hyperemia 
induced by SD in normal brain, which could confer ben-
efit to the tissue. The counterpoint was raised that if the 
SD is inhibited by ketamine in the first place, then per-
haps the hyperemia-blunting effect is a moot point, given 
the widely held theory that the hyperemic response is the 
compensatory mechanism for the enormous metabolic 
load of SD.
Other therapeutic options besides ketamine that were 
discussed revolved around optimization of systemic 
physiology. It was noted that both pre-clinical and clini-
cal data have supported an association of SD with factors 
such as hypotension, decreased cerebral perfusion pres-
sure, hypoglycemia, and elevated body and brain tem-
perature. Several clinicians mentioned that, in the case 
of SD detection, a reasonable first-line response would 
be aggressive normalization of these variables. While 
achieving normal systemic physiology is a cornerstone of 
routine neurocritical care, it was noted that the “normal” 
target ranges for these variables can actually be quite 
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wide, and that optimal values may be narrower and even 
differ between patients. One idea was that detection of 
SDs, as a potential indicator of brain injury progression, 
would lead to more aggressive or targeted management 
of these variables. Examples include fever control and 
elevation of cerebral perfusion pressure, even if already 
above the accepted minimum threshold. A concern 
was raised about “supranormal” responses, particularly 
related to glucose augmentation to levels higher than 
180 m/gL. Similarly, detrimental effects of hypothermia, 
induced hypertension, and prolonged hyperoxia are pos-
sible. To date, no studies have investigated whether phys-
iologic therapies can alter the course of SDs in patients.
While there are potential risks and benefits with any 
treatment, there was general agreement, given the pre-
ponderance of current data supporting a harmful role 
of SDs in some patients, that clinical studies of interven-
tions are warranted and needed. Thus, a major theme of 
the discussion was how to design an interventional clini-
cal trial, as summarized in the following sections.
Patient Population
There was acknowledgement that patients who undergo 
ECoG monitoring are extremely diverse, and different 
approaches, both in terms of clinical care and research 
priorities, may vary along this spectrum. Malignant 
hemispheric stroke patients appear to almost universally 
experience SD and have generally poor outcomes due 
to the severity of the baseline condition. With “little to 
lose and much to gain,” it was suggested that this group 
might be appropriate for a safety or feasibility study. 
Aneurysmal subarachnoid hemorrhage was discussed as 
an attractive disease for a neuroprotective interventional 
study, considering the well-recognized secondary phase 
of delayed cerebral ischemia (DCI). Since SD is involved 
in DCI pathogenesis, DCI could serve as a relevant study 
endpoint. Furthermore, its delayed nature allows docu-
mentation and study of its development, as well as time 
for early intervention. Most likely, a feasibility trial should 
be conducted first before a large multicenter outcome 
study. Traumatic brain injury was also discussed as a pri-
ority for research, considering the disease incidence and 
patient availability. A drawback of brain trauma, however, 
is its wide heterogeneity in causes, patient demograph-
ics, and intracranial pathologies. There was agreement 
that any study should aim to focus on a specific, more 
homogeneous population. One suggestion, based on the 
work presented at this iCSD meeting, was patients with 
chronic subdural hematoma. Ongoing brain trauma reg-
istries such as TRACK-TBI and CENTER-TBI were dis-
cussed as important efforts toward improved definition 
of patient subgroups for therapeutic targeting. Intracer-
ebral hemorrhage was proposed as a more homogenous 
disease; however, indications for surgery remain unclear 
for this condition.
Precision Medicine Versus Generalizability
Another key topic discussed in trial design was the 
role of “precision medicine” approaches, as opposed to 
broadly generalizable studies. There was a strong opin-
ion from some that the use of SD monitoring would be 
highly desirable in any interventional study, both to iden-
tify appropriate patients and to assess response to treat-
ment. Proponents of this “precision medicine” approach 
argued that selecting patients with SDs, or a high SD bur-
den, would identify the group most likely to benefit from 
therapy, and would further match the control group to 
the corresponding outcome risk. It was noted that pre-
vious failed trials of NMDA receptor antagonists did 
not have such selection. On the other hand, it was con-
sidered that only a small percentage of patients likely to 
experience SDs have a clinical need for surgery, which 
allows the placement of ECoG monitors. Thus, use of SD 
monitoring would be very restrictive and would present 
a challenge for recruitment of adequate numbers that 
may be needed in an interventional study. Inclusion of 
all patients with severe injury, or even those with more 
moderate injuries, who may also be at risk for SD, would 
be more feasible. Nonetheless, the true incidence and 
burden of SDs in these other populations are unknown, 
and it was cautioned that SD incidences and burden 
should not be extrapolated from surgical cases to all 
severity grades of the respective diseases. Extrapolation 
of treatments, therefore, is similarly troublesome.
One approach discussed to address the problem of 
generalizability was the development of noninvasive 
methods for SD diagnosis. This has emerged as an 
important topic at the iCSD meeting, with most efforts 
focused on scalp electroencephalogram (EEG) and, to 
a lesser extent, near-infrared spectroscopy. Short of a 
direct diagnostic, it was also suggested that surrogate 
markers or predictors of SD would be useful, particu-
larly in the context of patient selection for clinical tri-
als. Such markers could be population based, such as 
demographics, injury characteristics, or severity grad-
ing, to identify patients at high risk for SDs. A specific 
example cited was the recent work using scalp EEG to 
identify subarachnoid hemorrhage patients who will 
develop delayed cerebral ischemia; the EEG changes are 
likely caused by SDs or at least identify those patients 
who are likely to develop them. This high-risk group 
could then be targeted without invasive monitoring 
in a clinical trial. Such an approach would necessarily 
include some patients who did not have SD, but on the 
other hand would be applicable to wider patient popu-
lations, particularly those without monitoring. There 
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was broad consensus that work to identify risk factors 
and surrogate markers of SD should be prioritized for 
future studies.
Outcome Measures
A final topic of discussion was the choice of appropri-
ate outcome measures to indicate treatment efficacy. 
Improvement in a standardized clinical measure such as 
the Glasgow Outcome Score or modified Rankin Scale 
was discussed as the ultimate requirement, but several 
considerations reduced enthusiasm for such generalized 
measures as near-term goals. One consideration was 
small patient numbers, as highlighted above. Another 
was that SDs relate more to specific lesions, and that 
based on the lesion size and location, they may not 
relate to gross functional outcomes in many patients. For 
instance, a right frontal lesion may not significantly affect 
functional outcome, but a small dominant temporal 
lesion with expansion into language regions could theo-
retically result in a preventable aphasia. A third concern 
was that outcomes would be strongly influenced by phy-
sician interventions, practice variability, and other injury 
factors that typically are not well controlled in clinical 
trials. Discussants thus urged careful documentation of 
sedation medications, blood pressure medications, and 
nimodipine in particular, in both observational and inter-
ventional trials, and warned about implications of such 
variability for translation of pre-clinical results. Clinical 
variables should be controlled and documented as much 
as possible, deviations from normal should be corrected, 
and normalization of data and results to a patient’s base-
line may help. Conversely, pre-clinical studies should aim 
to replicate clinical conditions, for instance, in choice of 
anesthetics.
As an alternative to global outcome measures, it was 
proposed that imaging measures of intracranial lesions 
be used to assess benefit of SD-targeted treatments. The 
rationale for this approach is that the outcome measure 
should be linked closely to the targeted mechanism, and 
SDs are associated with lesion development and edema. 
Ideally, early and late imaging should be performed so 
that a patient can serve as his/her own baseline, and 
changes can be assessed over the period of treatment and 
monitoring. It was cautioned that this entails a large work 
burden to obtain images and quantify lesions, particu-
larly when lesions are smaller and require magnetic reso-
nance imaging. However, this may be the highest quality 
science and could be implemented in a smaller feasibility 
study.
Other Considerations
Support for an interventional trial was not unanimous, 
as one participant questioned the ethics of withholding 
treatment in some patients, as would be necessary in a 
control arm. It was suggested that watching a patient with 
multiple SDs that induce a progressive flattening of the 
ECoG recordings would be similar to watching a patient 
with intracranial pressure rising to 40 or 50 mmHg with-
out taking appropriate countermeasures. A few other 
concerns for trial design were also expressed. One was 
based on a case presented at the meeting, in which SDs 
were effectively suppressed at the location of a subdural 
ECoG strip, yet continued to occur at a separate location 
monitored with a depth electrode. This raised the possi-
bility of false positives in SD suppression, and suggested 
the need for more widespread ECoG monitoring of 
affected tissue than is provided by a single subdural strip. 
Another participant, in a related comment, suggested 
that the location of electrode strip placement should be 
standardized, as practice variance between centers could 
impact results.
Conclusions
There was fear that accumulating clinical evidence for 
the adverse effect of SDs, at least some patterns in some 
patients, together with increasing clinical use of keta-
mine, could lead to an overly enthusiastic and oversim-
plified view that “all SDs are bad and should be treated 
with ketamine.” Without an adequate evidence base, this 
scenario could be bad for patients and damaging to this 
promising field of translational neuroscience. There was 
consensus for the need for the field to move forward and 
scientifically determine the best method and clinical ben-
efit of interventions targeted at SD pathology. The clini-
cal science of SD represents one of the most promising 
opportunities for implementing a precision medicine 
approach to neuroprotection in acute brain injury, yet 
faces some acknowledged pitfalls, including challenges 
in generalizability. There was considerable support for 
studies utilizing real-time SD monitoring, and given the 
complexities of such a trial conducted at multiple cent-
ers, there was agreement that a feasibility study should 
be considered first. A specific trial discussed was the use 
of ketamine, in combination with midazolam, as the pre-
ferred sedative for patients in whom SDs are observed. 
Nonetheless, a diversity of opinions were expressed in 
this discussion, reflecting the wide range of expertise and 
the early-stage development of the field.
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